Summary
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are:
- How many participants' cancers respond to vidutolimod together with cemiplimab?
- Is vidutolimod together with cemiplimab safe and well-tolerated?
- How well does vidutolimod together with cemiplimab treat participants' cancer?
Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Official Title
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Details
Former Sponsor Checkmate Pharmaceuticals
Keywords
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, vidutolimod, Metastatic Cancer, Advanced Cancer, MCC, CSCC, BCC, TNBC, NSCLC, Carcinoma, Triple Negative Breast Neoplasms, Neoplasm Metastasis, Cemiplimab, Vidutolimod and cemiplimab for cutaneous squamous cell carcinoma (CSCC) (A1), Vidutolimod and cemiplimab for CSCC (A2), Vidutolimod and cemiplimab for Merkel cell carcinoma (MCC) (B1), Vidutolimod and cemiplimab for MCC (B2), Vidutolimod and cemiplimab for triple negative breast cancer (TNBC) (C1), Vidutolimod and cemiplimab for TNBC (C2), Vidutolimod and cemiplimab for basal cell carcinoma (BCC) (D), Vidutolimod and cemiplimab for non-small cell lung cancer (NSCLC)(E)